EUVIMEDEUVIMED entdecken
Crossref

RMST for Interval‐Censored Data in Oncology Clinical Trials

Xiyuan Gao, Tianmeng Lyu iD, Menghao Xu, Lisa V Hampson, Yan Du, Renxin Lin, Nigel Yateman, Lu Tian iD, Jianguo Sun iD

Statistics in Medicine · 2025

DOI: 10.1002/sim.70012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Xiyuan Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics, University of Missouri-Columbia, Columbia, Missouri, USA. Hauptthemen laut MEDLINE: Neoplasms, Medical Oncology, Clinical Trials as Topic. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In oncology studies, the assumption of proportional hazards is often questionable due to factors such as the presence of cured patients, a delayed treatment benefit, and possible treatment switching. The restricted mean survival time (RMST) has emerged as a valuable alternative summary measure to the hazard ratio (HR) in this scenario as it provides a clinically meaningful interpretation of treatment benefit without additional assumptions. As a commonly used primary endpoint, progression‐free survival (PFS) is defined as the time from randomization to the first occurrence of death or progression of disease (PD). However, PFS involves dual observation processes where, in practice, the exact death time is typically recorded, but PD is interval‐censored. This feature is also present in other commonly used primary endpoints, including event‐free survival, disease‐free survival, and relapse‐free survival. The conventional approach imputes the PD time with the right boundary of the time interval during which the PD occurs. This paper presents alternative estimation and inference approaches to estimate RMST with a mixture of right‐censored and interval‐censored data. Different approaches are explored by simulation under various plausible scenarios for oncology clinical trials with regard to the assessment frequency, randomness in the actual assessment times, and size of treatment effect. The choice of the restricted time point in RMST is also explored. The simulation results indicate that the RMST estimators that take account of the interval censoring inherent in the data are unbiased and more accurate than the conventional estimators, while the performance for two‐group comparisons is comparable. Furthermore, the performance of the proposed estimators is contingent on the scheduled assessment plan and patients' visit window.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsMedical OncologyClinical Trials as TopicHumansComputer SimulationProgression-Free SurvivalProportional Hazards ModelsSurvival AnalysisData Interpretation, StatisticalRandomized Controlled Trials as TopicDisease-Free SurvivalModels, Statistical

Stichwörter der Autor:innen

interval censoringoncology trialsprogression‐free survivalrestricted mean survival timesurvival function interpolation

Autor:innen und Institutionen

  • Department of Statistics, University of Missouri-Columbia, Columbia, Missouri, USA.
  • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • School of Statistics, East China Normal University, Shanghai, China.
  • Novartis Pharma AG, Basel, Switzerland.
  • Novartis Institutes for Biomedical Research Co., Shanghai, China.
  • Department of Biomedical Data Science, Stanford University, Stanford, California, USA.

ORCID-Profile: Tianmeng Lyu, Lu Tian, Jianguo Sun

Zitieren

APA

Gao, X., Lyu, T., Xu, M., Hampson, L. V., Du, Y., Lin, R., Yateman, N., Tian, L., & Sun, J. (2025). RMST for Interval‐Censored Data in Oncology Clinical Trials. Statistics in Medicine. https://doi.org/10.1002/sim.70012

Vancouver

Gao X, Lyu T, Xu M, Hampson LV, Du Y, Lin R, et al. RMST for Interval‐Censored Data in Oncology Clinical Trials. Statistics in Medicine. 2025. doi:10.1002/sim.70012

BibTeX
@article{Gao2025,
  author = {Gao, Xiyuan and Lyu, Tianmeng and Xu, Menghao and Hampson, Lisa V and Du, Yan and Lin, Renxin and Yateman, Nigel and Tian, Lu and Sun, Jianguo},
  title = {RMST for Interval‐Censored Data in Oncology Clinical Trials},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70012}
}
Kostenlos starten →